Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
150 participants
INTERVENTIONAL
2019-03-18
2020-01-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Misoprostol Solution in Comparison to Vaginal Misoprostol in Induction of Labor
NCT03863392
Comparison Between Vaginal Misoprostol Gel and Oral Misoprostol Solution in Induction of Labor
NCT06874049
Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor
NCT02036437
Efficacy and Safety of Titrated Oral Misoprostol Solution for Labor Induction at Term
NCT01070472
Vaginal Misoprostol With Intracervical Foley Catheter in Induction of Labor
NCT03682718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
repetitive hourly dose of oral misoprostol
The dose will be 10 microgram oral misoprostol that will be administered hourly up to 12 doses or till onset of regular uterine activity.
Misoprostol
This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.
Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.
Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity.
two hourly dose of oral misoprostol
The dose will be 20 microgram oral misoprostol solution that will be administered every 2 hours up to 6 doses or till onset of regular uterine activity.
Misoprostol
This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.
Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.
Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Misoprostol
This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.
Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.
Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Term pregnancy(equal or more than 37 wks)
* Bishop score \<6
* Cephalic presentation
* reassuring fetal heart rate pattern
* Not in labor ( no uterine contractions)
* Clinically adequate pelvis
* Singleton live pregnancy
Exclusion Criteria
* Previous uterine scar( cesarean section,hysterotomy,myomectomy)
* Multiple fetal gestations
* Fetal demise
* Preterm labor
* Malpresentations
* Non reactive cardiotocography at admission
* Cephalo pelvic disproportion
* Fetal macrosomia
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esam salah mohamed hagag
Director,clinical research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
essam sa hagag, MBBCh
Role: PRINCIPAL_INVESTIGATOR
Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
27986461
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
misoprostol in induction
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.